Genzyme Builds New Manufacturing Facility As Takeover Deadline Approaches
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgium-based plant will be used to manufacture Myozyme and Lumizyme for Pompe disease, a franchise that Genzyme says has the potential to become a blockbuster.
You may also be interested in...
Sanofi Extends $69-Per-Share Tender Offer For Genzyme To Jan. 21
Less than 1% of outstanding shares had been tendered as of Dec. 10 deadline.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.